HER2, Breast Cancer and PFS

First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE).
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Novel antibody reduces tumor growth in treatment-resistant breast and ovarian cancers
Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...
News Medical on MSN1d
IgE antibodies show promise in targeting HER2 cancers resistant to other therapies
Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.
Targeted Oncology1d
HER2DX Test Transforms Treatment Decisions in HER2+ Breast Cancer
A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a ...
OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3
OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative ...